Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2009 | 1 |
2010 | 1 |
2011 | 1 |
2012 | 1 |
2015 | 1 |
2024 | 0 |
Search Results
4 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Did you mean
ling ming tseng
(221 results)?
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.
Lancet. 2012 Feb 18;379(9816):633-40. doi: 10.1016/S0140-6736(11)61847-3. Epub 2012 Jan 17.
Lancet. 2012.
PMID: 22257673
Free PMC article.
Clinical Trial.
Phase II study of docetaxel, capecitabine, and cisplatin as neoadjuvant chemotherapy for locally advanced breast cancer.
Lu YS, Chen DR, Tseng LM, Yeh DC, Chen ST, Hsieh CM, Wang HC, Yeh HT, Kuo SH, Huang CS.
Lu YS, et al. Among authors: tseng lm.
Cancer Chemother Pharmacol. 2011 Jun;67(6):1257-63. doi: 10.1007/s00280-010-1401-2. Epub 2010 Aug 11.
Cancer Chemother Pharmacol. 2011.
PMID: 20700740
Clinical Trial.
Item in Clipboard
ErbB2-mediated Src and signal transducer and activator of transcription 3 activation leads to transcriptional up-regulation of p21Cip1 and chemoresistance in breast cancer cells.
Hawthorne VS, Huang WC, Neal CL, Tseng LM, Hung MC, Yu D.
Hawthorne VS, et al. Among authors: tseng lm.
Mol Cancer Res. 2009 Apr;7(4):592-600. doi: 10.1158/1541-7786.MCR-08-0316.
Mol Cancer Res. 2009.
PMID: 19372587
Free PMC article.
Item in Clipboard
Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.
Hurvitz SA, Andre F, Jiang Z, Shao Z, Mano MS, Neciosup SP, Tseng LM, Zhang Q, Shen K, Liu D, Dreosti LM, Burris HA, Toi M, Buyse ME, Cabaribere D, Lindsay MA, Rao S, Pacaud LB, Taran T, Slamon D.
Hurvitz SA, et al. Among authors: tseng lm.
Lancet Oncol. 2015 Jul;16(7):816-29. doi: 10.1016/S1470-2045(15)00051-0. Epub 2015 Jun 16.
Lancet Oncol. 2015.
PMID: 26092818
Clinical Trial.
Item in Clipboard
Cite
Cite